Use of piperacillin-tazobactam (Zosyn) likely less effective than meropenem for ceftriaxone-resistant gram-negative bacteremia
1. In this randomized controlled trial, piperacillin-tazobactam was not found to be non-inferior to meropenum for all-cause mortality at 30 ...
